By Natalie Johnson
Eight years ago, Frederic Scheer survived stage four cancer after enduring radiation, chemotherapy, and a prolonged recovery. “What I remember the most is not the treatment,” he says. “It’s the month in which my body was already changing and no one could see it.” That experience shaped his conviction that predicting cancer years in advance could fundamentally reshape patient outcomes. Cancer diagnostics have traditionally focused on identifying the disease after symptoms emerge or tumors become visible through imaging. Scheer says that approach is already becoming obsolete.
As Chief Executive Officer (CEO), Chief Scientific Officer (CSO), and Co-Founder of ALERCELL, the biotech entrepreneur is advancing a form of predictive diagnostics designed to detect molecular changes years before a clinical diagnosis ever arrives. “The future of oncology is not faster treatment, it’s earlier visibility,” Scheer says. Three-and-a-half years to be exact. According to ALERCELL’s data, three-and-a-half years is the average interval between the first measurable epigenetic drift in peripheral blood and the moment a hematologist orders a bone marrow biopsy. For patients, that gap represents survival, choice, and a radically different relationship with cancer itself.
From Fire Alarms to Smoke Detectors
Scheer describes modern cancer diagnosis as reactive medicine, meaning that by the time most hematologic malignancies are discovered, treatment options often become more aggressive, more invasive, and less personalized. “A diagnosis today is a fire alarm,” he says. “What we are building is a smoke detector calibrated to the chemistry, not to the flame.” That distinction sits at the heart of ALERCELL’s AI-powered molecular diagnostics platform. Instead of searching only for visible tumors or established mutations, the company focuses on epigenetics, specifically methylation drift that may indicate the earliest biological signs of disease.
The implications for leukemia screening and blood cancer at large monitoring are substantial. Catching cancer before symptoms appear could move five-year survival rates from the 30% to 40% range into the 70% to 90% range, depending on the subtype. Earlier cancer diagnosis saves lives not simply because treatment begins sooner, but because patients gain options before the disease escalates. Patients may pursue watchful waiting, targeted therapies, or lifestyle interventions instead of emergency chemotherapy regimens. “Ambient anxiety gets replaced with a quantified trajectory and a defined surveillance plan,” Scheer says.
How AI Detects Cancer Early
“DNA is the hardware of the cell,” he says. “Methylation is the software.” While genetics reveal what a tumor is made of, epigenetics may reveal what the body is becoming. ALERCELL’s LENA platform, short for Leukemia Epigenetic Navigational Algorithm operates across three layers. The LENA Clock measures biological age through blood analysis. The LENA Code evaluates methylation patterns across 48 carefully selected CpG sites associated with cancer biomarkers and preclinical detection. The LENA Score combines those findings into an interpretable risk trajectory.
By comparing blood samples over time, the platform measures how quickly biological patterns are drifting, how disordered they are becoming, and how close they may be to a tipping point. “What we do is closer to weather forecasting than weather reporting,” Scheer says. “The diagnostic snapshot tells you the temperature. We model the system, watch the pressure changes, and tell you what is likely to happen next.”
The Three Forces Driving Predictive Oncology
“Timing in biotech is not a matter of style,” Scheer says. “It is a precise moment when cost, data, and policy align.” He points to a convergence of three forces that made this moment possible. This alignment has accelerated competition across the multi-cancer early detection market, where companies are racing to redefine how healthcare systems approach early detection and predictive diagnostics:
1. The cost of high-resolution methylation profiling has dropped dramatically, making clinical-scale testing commercially viable.
2. ALERCELL validated its platform across more than 199,000 real-world electronic medical records, creating a data foundation that extends beyond curated research samples.
3. Regulation has started catching up. Montana’s SB535 legislation created a phase-one-to-patient pathway that allows companies to validate technologies under real clinical conditions while pursuing FDA approval simultaneously.
Rethinking How We Screen for Cancer
Scheer is careful not to frame ALERCELL as competing directly with every other cancer detection company entering the market. Instead, he positions the company within an adjacent category focused on trajectory analysis rather than binary diagnosis.
“Most MCED platforms ask one question: Is cancer present today?” he says. “We ask a different question: Where is biology heading?” That difference may ultimately reshape how annual physicals operate in the future of precision oncology. Rather than relying solely on age-based schedules for mammograms or colonoscopies, physicians could eventually use biology-driven surveillance models personalized to each patient.
A routine checkup five years from now, Scheer predicts, may include biological age measurements, trajectory mapping, and bifurcation proximity scores showing how close a patient is to elevated cancer risk. “The annual physical stops being a snapshot and becomes a frame in a movie,” he says.
The science supporting NSCLC early detection technology and diagnosing leukemia before it spreads continues advancing rapidly. The remaining challenge may be structural rather than scientific. Reimbursement systems, insurance coverage, and healthcare payment infrastructure remain years behind the pace of innovation.
Still, the direction is inevitable. From detection to prevention in oncology, medicine is gradually shifting toward continuous biological surveillance rather than episodic diagnosis. “We are not trying to cure cancer faster,” he says. “We are trying to make sure fewer people ever need the cure.”
Follow Frederic Scheer on LinkedIn or visit his website for more insights.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Readers should consult a qualified healthcare professional for guidance on cancer screening, diagnostic testing, or any health concerns specific to their situation.
